Phase 1 Study to Investigate ABS-101 in Healthy Adult Participants

ABS-101 is a new experimental biologic medication being developed as a potential treatment for inflammatory conditions. Before it can be tested in patients, its safety and how the body processes it need to be carefully studied in healthy volunteers — this is called a first-in-human study. This Phase 1 trial will test single and then gradually increasing doses of ABS-101 in healthy adults to find out how well it is tolerated, what dose levels are safe, and how the body absorbs, distributes, and eliminates it. The results will guide the dose used in future patient trials. Participants will have vital signs, blood tests, and ECGs monitored throughout. You may be eligible if you are a healthy adult aged 18 to 65 with a BMI of 18–32, weigh at least 60 kg, and test negative for drug use, alcohol, and nicotine. People with liver conditions, HIV, hepatitis B or C, or who are pregnant, are not eligible. Since the medication targets the immune pathway TL1A, prior exposure to any anti-TL1A therapy also disqualifies participation.